Emerging Themes in Targeted Therapy Research for CLL

Video

John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Cancer Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses some emerging themes in research for targeted therapies as a treatment for patients with chronic lymphocytic leukemia (CLL).

Targeted agents are here to stay, says Seymour. These agents are more effective, safer, and are less genotoxic than treatment with chemoimmunotherapy.

Recent Videos
Related Content
The Clinical Impact of Biased Language in Handoffs

The Clinical Impact of Biased Language in Handoffs

Austin Littrell
February 10th 2025
Article

Negative language about patients can reduce clinician empathy and recall of critical health details, a recent study finds.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Phase 3 waveLINE-010 Study Starts for Zilovertamab Vedotin in DLBCL

Phase 3 waveLINE-010 Study Starts for Zilovertamab Vedotin in DLBCL

Jordyn Sava
February 7th 2025
Article

The phase 3 waveLINE-010 trial is evaluating zilovertamab vedotin plus R-CHP vs R-CHOP for the treatment of untreated diffuse large B-cell lymphoma.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

The Value of Clinical Pharmacists in Community Oncology

The Value of Clinical Pharmacists in Community Oncology

Jordyn Sava
February 5th 2025
Article

Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into community oncology practices.

Read More

Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison

Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison

Targeted Oncology Staff
February 4th 2025
Article

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.

Read More